research use only

DM1 (Mertansine) Microtubule Associated inhibitor

Name: DM1 (Mertansine)
Brand: Selleck Chemicals
SKU: S6773
Rating: 5 (1 reviews)

Cat.No.S6773

DM1 (Mertansine), an antibody-conjugatable maytansinoid, is a selective microtubule inhibitor developed to overcome systemic toxicity associated with maytansine and to enhance tumour-specific delivery. It can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC).Solutions are unstable and should be fresh-prepared.

Chemical Structure

Molecular Weight: 738.29

Jump to

Quality Control

Batch: S677301 DMSO]50 mg/mL]false]Ethanol]2 mg/mL]false]Water]Insoluble]false Purity: 99.84%

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

99.84

Related Targets	Akt Wnt/beta-catenin PKC HSP ROCK Integrin Bcr-Abl Actin FAK Kinesin
Other Microtubule Associated Inhibitors	Nocodazole MMAF Patupilone (Epothilone B) Lexibulin (CYT997) CW069 Combretastatin A4 Epothilone A ABT-751 (E7010) TAI-1 Cucurbitacin B

Chemical Information, Storage & Stability

Molecular Weight	738.29	Formula	C₃₅H₄₈ClN₃O₁₀S	Storage (From the date of receipt)	3 years-20°C powder
CAS No.	139504-50-0	--		Storage of Stock Solutions	Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.
Synonyms	Maytansinoid DM1			Smiles	COC1\C=C\C=C(C)\CC2=CC(=C(Cl)C(=C2)OC)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCS)C3(C)OC3C(C)C4CC1(O)NC(=O)O4

Solubility

In vitro
Batch:

DMSO : 50 mg/mL (67.72 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 2 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.500mg/ml (3.39mM)	Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.250mg/ml (1.69mM)	Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Microtubule
References	[1] https://pubmed.ncbi.nlm.nih.gov/20937594/ [2] https://pubmed.ncbi.nlm.nih.gov/21481526/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06138743	Recruiting	Myotonic Dystrophy 1	Arrowhead Pharmaceuticals	March 4 2024	Phase 1
NCT05532813	Not yet recruiting	Steinert''s Disease\|Myotonic Dystrophy 1\|Metformin	Assistance Publique - Hôpitaux de Paris	March 2024	Phase 3
NCT06204809	Recruiting	Myotonic Dystrophy 1	PepGen Inc	December 12 2023	Phase 1
NCT06270186	Withdrawn	Myotonic Dystrophy 1	Centre Hospitalier Universitaire de Nice	November 2023	Not Applicable
NCT05945927	Recruiting	Breast Cancer	Hoffmann-La Roche	September 13 2023	--

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):